• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Clopidogrel-Teva 75mg 90 tablets — Made in Czech Republic — Free Delivery

    Clopidogrel-Teva 75mg 90 tablets — Made in Czech Republic — Free Delivery


    Brand: TEVA
    Product Code: Clopidogrel-Teva
    Availability: In Stock
    $21.88
    Add to Cart

    Product description

    Clopidogrel-Teva tablets are used for the indications listed below.
    Prevention of manifestations of atherothrombosis in adults:
    • in patients who have had myocardial infarction (start of treatment - a few days, but no later than 35 days after onset), ischemic stroke (start of treatment - 7 days, but no later than 6 months after onset), or who have been diagnosed with peripheral arterial disease (arterial disease and atherothrombosis of the vessels of the lower extremities);
    • in patients with acute coronary syndrome:
    • with acute coronary syndrome without ST segment elevation (unstable angina pectoris or myocardial infarction without Q wave), including in patients who received a stent during percutaneous coronary angioplasty in combination with acetylsalicylic acid (ASA);
    • with acute myocardial infarction with ST segment elevation in combination with acetylsalicylic acid (in patients receiving standard medical treatment and for whom thrombolytic therapy is indicated).
    Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASA is indicated in adult patients with atrial fibrillation who have at least one risk factor for vascular events, for whom treatment with vitamin K antagonists (VKA) is contraindicated and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events, including stroke.

    Structure

    Active substance: clopidogrel;
    1 tablet contains 97.86 mg of clopidogrel bisulfate, which is equivalent to 75 mg of clopidogrel;
    Excipients: lactose, microcrystalline cellulose, crospovidone, glycerin dibegenate, talc;
    Sheath: Opadry II 85G34669 pink (polyvinyl alcohol, talc, macrogol 3350, lecithin, titanium dioxide (E 171), iron oxide red (E172)).

    Contraindications

    hypersensitivity to the active substance or to any component of the drug;
    severe liver failure;
    Acute bleeding (such as an ulcer or intracranial hemorrhage)

    Mode of application

    For adults and elderly patients, Klopidogrel-Teva should be prescribed 75 mg 1 time per day, regardless of food intake.
    In patients with acute coronary syndrome without ST-segment elevation (unstable angina pectoris or myocardial infarction without a Q wave on the ECG), clopidogrel treatment should be started with a single loading dose of 300 mg, and then continued at a dose of 75 mg once a day (with acetylsalicylic acid (ASA) at a dose of 75-325 mg per day). Since the use of higher doses of ASA increases the risk of bleeding, it is not recommended to exceed the ASA dose of 100 mg.
    The optimal duration of treatment has not been formally established. The results of clinical studies support the use of the drug for up to 12 months, and the maximum effect was observed after 3 months of treatment.
    In patients with acute myocardial infarction with ST-segment elevation, clopidogrel should be prescribed 75 mg once a day, starting with a single loading dose of 300 mg in combination with ASA, with or without thrombolytic drugs. Treatment of patients aged 75 years and older should be started without a loading dose of clopidogrel. Combination therapy should be started as early as possible after symptom onset and continued for at least 4 weeks. The benefit of the combination of clopidogrel with ASA for more than 4 weeks in this disease has not been studied.
    For patients with atrial fibrillation, use clopidogrel in a single dose of 75 mg. Together with clopidogrel, you should start and continue using ASA (at a dose of 75-100 mg per day).

    Application features

    Pregnant
    Due to the lack of clinical data on the use of clopidogrel during pregnancy, it is undesirable to prescribe the drug to pregnant women (precautions).
    It is not known whether clopidogrel is excreted in breast milk. In animal studies, it has been shown that it is excreted in breast milk, therefore, during treatment with Clopidogrel-Teva, breastfeeding should be discontinued.
    Children
    Clopidogrel should not be used in children, since there is no data on the effectiveness of the drug for this age group of patients.
    Drivers
    Clopidogrel does not affect or has a slight effect on the reaction rate when driving or operating other mechanisms.

    Overdose

    In case of an overdose of clopidogrel, there may be an increase in bleeding time with subsequent complications. In case of bleeding, symptomatic treatment is recommended.
    The antidote for the pharmacological activity of clopidogrel is unknown. If it is necessary to immediately correct the prolonged bleeding time, the action of clopidogrel can be stopped by transfusion of platelet mass.

    Side effects

    Bleeding was the most common adverse reaction observed in both clinical trials and post-marketing, during which it most often occurred in the first month of treatment.

    Storage conditions

    Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
    Shelf life is 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017